Home / Health / Cheaper Weight Loss Pills Spur Patient Switches
Cheaper Weight Loss Pills Spur Patient Switches
21 May
Summary
- Novo Nordisk and Eli Lilly's lower-priced oral weight-loss pills attract patients.
- Insurance coverage remains a significant hurdle for many patients.
- New government Medicare coverage program for GLP-1s begins in July.
Patients are shifting from compounded weight-loss drugs to branded oral medications from Novo Nordisk and Eli Lilly. The lower price points of Wegovy and Foundayo, often on par with compounded versions, are attracting these patients, especially as insurance coverage for these treatments remains a significant obstacle.
Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo launched in January and April, respectively, and are seeing robust demand. While branded drugs are subject to greater oversight, their more accessible pricing is appealing. Doctors note that Wegovy benefits from strong brand recognition and existing heart-protective data.
Despite the shift, insurance coverage is a persistent issue, with many patients facing rejections. However, a new U.S. government program providing Medicare coverage for GLP-1s, scheduled to start in July and run through 2027, is anticipated to boost commercial coverage.
While some patients on injectable GLP-1s are switching to the pills, this is not widespread, as many are satisfied with their current treatments. Experts suggest these oral options are expanding the overall market for GLP-1s, attracting patients previously deterred by price.
